Pliant Therapeutics (NASDAQ:PLRX) Posts Earnings Results, Misses Estimates By $0.02 EPS

Pliant Therapeutics (NASDAQ:PLRX) released its quarterly earnings results on Thursday. The company reported ($0.39) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.37) by ($0.02), FiscalAI reports.

Pliant Therapeutics Stock Performance

Pliant Therapeutics stock traded down $0.04 during trading hours on Thursday, reaching $0.74. 525,019 shares of the stock were exchanged, compared to its average volume of 548,164. The stock has a market cap of $45.82 million, a P/E ratio of -0.50 and a beta of 1.36. Pliant Therapeutics has a 52-week low of $0.73 and a 52-week high of $1.80. The firm’s 50 day moving average is $0.99 and its 200 day moving average is $1.14.

Analyst Ratings Changes

PLRX has been the subject of several analyst reports. Weiss Ratings reaffirmed a “sell (e+)” rating on shares of Pliant Therapeutics in a research note on Thursday, October 15th. Wall Street Zen downgraded Pliant Therapeutics from a “hold” rating to a “sell” rating in a research note on Saturday, November 7th. One equities research analyst has rated the stock with a Buy rating, one has assigned a Hold rating and one has given a Sell rating to the company’s stock. According to MarketBeat, the stock presently has a consensus rating of “Hold” and a consensus price target of $3.00.

About Pliant Therapeutics

Pliant Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on discovering and developing therapies for fibrotic diseases. The company’s research is centered on integrin biology, a field involving proteins that regulate cell communication and tissue remodeling. Pliant aims to develop medicines that address the underlying processes that drive fibrosis in organs such as the lungs and liver. Pliant’s lead investigational product is bexotegrast, an oral, selective inhibitor of the integrins αvβ1 and αvβ6.